B7-33
B7-33 is a single-chain relaxin-2 B-chain analogue studied as a functionally selective RXFP1 agonist. The cited work covers receptor pharmacology, preclinical vascular models and myocardial-infarction-related remodeling in mice; it does not establish human efficacy. The price list contains three materially different labels: 2 / Injectable (Lyophilized Powder), 5 / Powder and 6 / Injectable (Lyophilized Powder). It does not state the dosage unit, full sequence or terminal modifications, so those details must be resolved for each quote.
Technical Specifications
| Class | Single-chain relaxin-2 B-chain analogue studied as a functionally selective RXFP1 agonist. |
| Exact analog identity | The quote must state the full sequence, N- and C-terminal modifications, counterion and calculated mass; the class name alone is incomplete. |
| Listed presentations | 2 / Injectable (Lyophilized Powder), 5 / Powder and 6 / Injectable (Lyophilized Powder). The dosage unit is not stated. |
| Identity evidence | Request batch LC-MS or an equivalent identity method and reconcile the observed mass with the exact quoted construct. |
| Content and impurities | Verify chromatographic area purity, net peptide content, related substances, water and residual solvents for the allocated lot. |
| Handling | Use the buffer, concentration, storage and in-use window supported for the exact supplied form and planned RXFP1 assay. |
Preclinical B7-33 and RXFP1 research
- Functionally selective RXFP1 signaling research
- Preclinical vascular-response models
- Myocardial-infarction-related cardiac-remodeling models in mice
- Relaxin-2 analog structure-function studies
Wholesale pricing and batch checks
Wholesale from $3.06
Published wholesale tiers apply when the order reaches 100+ total units; the tier is selected by quantity of each SKU. Smaller total orders are quoted separately.
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 2 / Injectable (Lyophilized Powder) | $4.08 | $3.57 | $3.06 |
| 5 / Powder | $6.80 | $5.95 | $5.10 |
| 6 / Injectable (Lyophilized Powder) | $7.48 | $6.54 | $5.61 |
What to verify before ordering B7-33
The class description “single-chain relaxin-2 B-chain analogue” does not fully identify a B7-33 material. The sequence, termini and exact supplied form determine whether a quote matches a published construct or assay.
- Exact construct
Request the full sequence, terminal modifications, counterion, calculated mass and batch identity result. Reconcile every quoted presentation with that same construct definition.
- Analytical package
Review the identity result, HPLC method and chromatogram, net peptide content, related substances, water and residual-solvent data for the allocated lot.
- Assay compatibility
Specify the RXFP1 assay format, buffer constraints, concentration range, vial fill and handling window. Literature-derived activity cannot replace a batch-specific qualification result.
The cited studies report model- and construct-specific preclinical findings. They do not establish human efficacy or safety and do not verify an independently supplied lot.
Research evidence for B7-33
Hossain et al. (2016). A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Chemical Science. DOI: 10.1039/C5SC04754D
Study scope: RXFP1 signaling and pharmacology experiments performed with the paper's defined B7-33 construct. The single-chain relaxin-2 B-chain analogue defined and used in the reported experimental systems.
What it supports: Supports describing B7-33 as a functionally selective RXFP1 agonist within the study's receptor and signaling experiments.
Boundary: The paper does not establish clinical efficacy, interchangeability among unspecified analogs, or identity of a supplier batch.
Sarwar et al. (2017). B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin). European Journal of Pharmacology. DOI: 10.1016/j.ejphar.2017.05.005
Study scope: Rat and mouse vascular preparations used to compare the defined B7-33 construct with human relaxin-2 or serelaxin. Study-defined B7-33 material, doses and experimental preparations.
What it supports: Supports a bounded statement about vascular-response observations in the reported rat and mouse models.
Boundary: The findings do not prove human vasoprotection, a therapeutic dose, or performance of an independently sourced lot.
Martin et al. (2020). B7‐33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction–Related Adverse Cardiac Remodeling in Mice. Journal of the American Heart Association. DOI: 10.1161/JAHA.119.015748
Study scope: Mice in a myocardial-infarction-related adverse cardiac-remodeling model. The B7-33 construct, route and dose used in the reported mouse protocol.
What it supports: Supports discussing adverse cardiac-remodeling findings only within that mouse model.
Boundary: A mouse outcome does not establish human cardiovascular efficacy, safety or equivalence with a commercial batch.
Frequently Asked Questions About B7-33
B7-33 is a single-chain relaxin-2 B-chain analogue studied at the RXFP1 receptor. A quote must still identify the exact sequence and terminal modifications.
It describes the signaling behavior reported for the defined B7-33 construct in receptor experiments. It is not a claim of established therapeutic selectivity in people.
The price list contains 2 / Injectable (Lyophilized Powder), 5 / Powder and 6 / Injectable (Lyophilized Powder). The dosage unit is not stated.
No. The cited vascular work is preclinical and the cardiac-remodeling paper reports a mouse model. Neither establishes human efficacy or safety.
Each of the three B7-33 forms has separate 10+, 25+ and 50+ per-SKU tiers. Published tiers apply when the order reaches 100+ total units; smaller total orders are quoted separately.
Confirm the full construct, observed mass, identity method, chromatographic area purity, net peptide content, impurities, supplied form and assay-specific handling instructions.